FogPharma

The AI engine Fit Assessment

Beta

FogPharma creates cell-penetrating mini proteins to target and neutralize cancer-causing proteins, offering new precision medicines for cancer treatment beyond conventional methods.

Blurb

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

HQ Location

Cambridge (United States)

Founded

2015

Employees

51 - 200

Total funding raised

$530.27M

Last Funding Event

Series E, $145.00M, March 1, 2024

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.